Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 1—January 2019
Dispatch

Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States

Eveliina Karelehto, Lieke Brouwer, Kimberley Benschop, Jen Kok, Kerri Basile, Brendan McMullan, William Rawlinson, Julian Druce, Suellen Nicholson, Rangaraj Selvarangan, Christopher Harrison, Kamani Lankachandra, Hetty van Eijk, Gerrit Koen, Menno de Jong, Dasja Pajkrt, and Katja C. WolthersComments to Author 
Author affiliations: Academic Medical Center, Amsterdam, the Netherlands (E. Karelehto, L. Brouwer, H. van Eijk, G. Koen, M. de Jong, D. Pajkrt, K.C. Wolthers); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (K. Benschop); Institute of Clinical Pathology and Medical Research, Westmead, New South Wales, Australia (J. Kok, K. Basile); Sydney Children's Hospital, Sydney, New South Wales, Australia (B. McMullan); Prince of Wales Hospital, Randwick, New South Wales, Australia (W. Rawlinson); Doherty Institute, Melbourne, Victoria, Australia (J. Druce, S. Nicholson); Children’s Mercy Hospital, Kansas City, Missouri, USA (R. Selvarangan, C. Harrison); Truman Medical Center, Kansas City (K. Lankachandra)

Main Article

Figure 1

Parechovirus A3 (PeV-A3 neutralizing antibody (nAb) seropositivity, Australia, the Netherlands, and United States. A) Overall nAb seropositivity with associated 95% CIs. Infants <1 year of age were excluded from the analysis. Seropositivity rates between the timepoints within each location were compared by using χ2 tests. B) Overall age-stratified PeV-A3 nAb seropositivity, including infants <1 year of age. Seropositivity was determined as a nAb titer of ≥1:8 or ≥1:32. C–F) Age-stratified

Figure 1. Parechovirus A3 (PeV-A3 neutralizing antibody (nAb) seropositivity, Australia, the Netherlands, and United States. A) Overall nAb seropositivity with associated 95% CIs. Infants <1 year of age were excluded from the analysis. Seropositivity rates between the timepoints within each location were compared by using χ2 tests. B) Overall age-stratified PeV-A3 nAb seropositivity, including infants <1 year of age. Seropositivity was determined as a nAb titer of ≥1:8 or ≥1:32. C–F) Age-stratified PeV-A3 nAb seropositivity in C) the Netherlands; D) Missouri, USA; E) Victoria, Australia; and F) New South Wales, Australia. Complete data used in this figure can be found in the Appendix (http://wwwnc.cdc.gov/EID/article/25/1/18-0352-App1.pdf). AUS, Australia; NL, the Netherlands; NSW, New South Wales; VIC, Victoria.

Main Article

Page created: December 17, 2018
Page updated: December 17, 2018
Page reviewed: December 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external